Introduction to Mirati Therapeutics Inc.

Mirati Therapeutics Inc. is a leading precision oncology company headquartered in San Diego, California, with a global footprint in the United States and Europe. Founded in 2013, Mirati quickly established itself as a powerhouse in developing targeted cancer therapies, particularly inhibitors for KRAS mutations—a notoriously difficult target in oncology. The company’s flagship product, adagrasib (Krazati), received accelerated FDA approval in 2022 for non-small cell lung cancer, marking a major breakthrough. In 2023, Mirati was acquired by Bristol Myers Squibb (BMS), integrating its innovative pipeline and expertise into a larger pharmaceutical ecosystem while retaining its brand and operational culture. Today, Mirati Therapeutics Inc. operates as a subsidiary of BMS, leveraging vast resources to accelerate drug development and commercialization. The company’s reputation for scientific rigor, patient-centric approaches, and cutting-edge research makes it a top employer in the Healthcare and Biotech industry. With a workforce of over 800 employees before the acquisition, Mirati continues to attract top talent from academia and industry. The company profile reflects a blend of entrepreneurial agility and corporate stability, ideal for professionals seeking impactful careers in oncology.

Company History and Business Evolution

Mirati Therapeutics Inc. was co-founded by Dr. Michael Wick and Dr. Charles Baum in 2013, with a vision to tackle the most challenging genetic drivers of cancer. The early years focused on building a proprietary discovery platform targeting the RAS/MAPK pathway, specifically KRAS G12C mutations. In 2018, Mirati presented promising preclinical data for adagrasib at major oncology conferences, attracting significant investor interest. The company went public on the NASDAQ (MRTX) in 2019, raising capital to advance clinical trials. A pivotal milestone came in December 2022 when the FDA granted accelerated approval for adagrasib for metastatic NSCLC. This approval was followed by rapid expansion of the pipeline into other KRAS-driven cancers and combination therapies. In October 2023, Bristol Myers Squibb announced a $5.8 billion acquisition of Mirati, a testament to the company’s value and potential. The acquisition closed in early 2024, integrating Mirati into BMS’s oncology division while preserving its San Diego base. Since then, Mirati has benefited from BMS’s manufacturing, global commercial infrastructure, and complementary pipelines. The company continues to explore novel targets like KRAS G12D and other undruggable mutations, positioning itself at the forefront of the next generation of cancer treatments.

Mirati Therapeutics Inc. at a Glance

• Headquarters: San Diego, California, USA
• Founded: 2013
• CEO (pre-acquisition): David Meek
• Parent Company: Bristol Myers Squibb (since 2024)
• Industry: Biotechnology / Oncology
• Employees: ~800 (pre-acquisition)
• Revenue (2023): Estimated $250 million (adagrasib sales)
• Key Product: Krazati (adagrasib) – KRAS G12C inhibitor
• Pipeline: KRAS G12D, MRTX1133, combination therapies
• Stock Ticker (former): NASDAQ: MRTX
• Core Technology: Small molecule inhibitors targeting RAS mutations
• Key Indications: Non-small cell lung cancer, colorectal cancer, pancreatic cancer
• Clinical Trials: Over 20 ongoing Phase I–III trials globally
• Partnerships: Array BioPharma, Novartis, BeiGene (formerly)
• Corporate Culture: Patient-centric, innovative, fast-paced
• Awards: Fierce 15 (2018), Best Places to Work (multiple years)
• Global Reach: US, EU, and emerging markets via BMS
• R&D Focus: Precision oncology, synthetic lethality, immunotherapy combinations
• Lab Facilities: San Diego headquarters with state-of-the-art research labs
• Employee Satisfaction: High ratings on Glassdoor and Indeed

Mission, Vision, and Core Corporate Values

Mirati Therapeutics Inc.’s mission is to discover, develop, and deliver life-changing therapies for cancer patients with high unmet needs. The vision extends beyond targeting KRAS: to become a leader in precision oncology, unlocking treatments for previously undruggable targets. Core values include Scientific Excellence—rigorous research and uncharted science; Patient Urgency—speed without compromising ethics; Collaboration—teamwork across disciplines and with partners; Integrity—transparency in data and compliance; and Courage—taking bold steps in drug discovery. These values guide decision-making from bench to bedside. The company actively promotes diversity and inclusion, with employee resource groups and mentorship programs. After joining BMS, these values remain intact, supported by a larger corporate governance framework.

Business Strategy and Future Roadmap

Mirati Therapeutics Inc.’s strategy combines internal discovery with strategic alliances. The company invests heavily in early-stage research to identify new targets, particularly within the RAS pathway. Post-acquisition, BMS provides financial stability enabling mid- and late-stage trials without the pressure of immediate profitability. The roadmap includes expanding adagrasib into frontline NSCLC and adjuvant settings, as well as combinations with immunotherapies and targeted agents. The pipeline’s crown jewel is MRTX1133, a KRAS G12D inhibitor, currently in Phase I. Additionally, Mirati explores synthetic lethality approaches and novel small molecules against mutant RAS. The company also leverages BMS’s global sales force to maximize Krazati’s market penetration. Future milestones include potential approvals in colorectal and pancreatic cancers, and further expansion into Europe and Asia. Mirati’s strategy emphasizes biomarker-driven patient selection, ensuring that its therapies reach those most likely to benefit.

Products, Technologies, and Services

Mirati Therapeutics Inc.’s primary product is Krazati (adagrasib), a potent and selective KRAS G12C inhibitor. Approved for second-line NSCLC, it is also being studied in first-line and in combination with pembrolizumab. The company’s technology platform includes structure-based drug design, ADME optimization, and biomarker strategies for patient stratification. Mirati also develops preclinical tools and assays for target engagement. Beyond small molecules, the company explores proteolysis-targeting chimeras (PROTACs) for RAS degradation. Services are not offered; Mirati is a drug developer, not a service provider. However, its clinical trials provide access to innovative treatments for patients globally. The company’s collaborations with diagnostic companies enable companion diagnostics for Krazati.

Industries and Markets Served

Mirati Therapeutics Inc. serves the oncology healthcare sector—hospitals, oncology clinics, and cancer centers. Its therapies target patients with specific genetic mutations: KRAS G12C, G12D, and future mutations. The primary market is the United States, followed by Europe and Asia (via BMS). Mirati’s treatments are used in non-small cell lung cancer, colorectal cancer, and pancreatic cancer. The company also impacts the biopharmaceutical industry by advancing understanding of RAS signaling and drug resistance. It serves as a model for targeted drug development in challenging areas.

Leadership and Management Philosophy

Mirati Therapeutics Inc.’s leadership pre-acquisition was headed by David Meek, former CEO, known for his strategic vision and commercial acumen. The management philosophy emphasizes empowerment, accountability, and transparency. Leaders encourage scientific debate and rapid decision-making. Post-acquisition, the integration with BMS has brought additional layers but retained a flat culture within the San Diego site. The R&D team, led by Chief Medical Officer Dr. Susan Galbraith (now part of BMS), fosters collaboration between discovery and clinical teams. Mirati’s management believes in investing in employee growth, providing continuous learning opportunities and cross-functional projects.

Corporate Events, Conferences, and Community Engagement

Mirati Therapeutics Inc. actively participates in major oncology conferences: ASCO, AACR, ESMO, and World Lung Cancer Conference. The company presents clinical data, hosts symposia, and engages with key opinion leaders. Community engagement includes patient advocacy partnerships with organizations like LUNGevity and Pancreatic Cancer Action Network. Mirati sponsors educational webinars and run/walk events to raise awareness and funds. The company also holds internal Scientific Symposia and Innovation Days to foster collaboration. Through BMS, it participates in corporate giving programs and volunteer days in San Diego.

Employees and Workplace Culture

Mirati Therapeutics Inc. fosters a culture of innovation, inclusion, and purpose. Employees describe the environment as fast-paced but supportive, with a flat hierarchy where ideas can be heard. The company offers competitive compensation, stock options, health benefits, and flexible work arrangements. Professional development is encouraged through mentorship, tuition reimbursement, and conference attendance. The San Diego headquarters features modern labs and collaborative workspaces. Diversity initiatives include employee resource groups for women, LGBTQ+, and underrepresented minorities. After the BMS acquisition, employees have access to larger career paths and resources while maintaining the nimble spirit of a biotech.

Job Details & Requirements for this Posting

Position: Senior Clinical Research Scientist

Location: San Diego, CA (Remote flexibility possible)
Job Type: Full-time
Reporting to: Clinical Development Director

Responsibilities:

• Lead the design and execution of clinical trials for novel oncology therapeutics, focusing on KRAS inhibitors.
• Develop clinical protocols, investigator brochures, and informed consent forms.
• Analyze clinical data and prepare abstracts, manuscripts, and regulatory submissions.
• Collaborate with translational medicine, biostatistics, and regulatory affairs teams.
• Present clinical findings at internal meetings and external conferences.
• Ensure compliance with GCP, ICH guidelines, and regulatory requirements.
• Mentor junior clinical scientists and contribute to team development.

Qualifications:

• PhD or PharmD in oncology, pharmacology, or related field (or MD with clinical trial experience).
• 5+ years of experience in clinical development within biotech or pharma.
• Deep understanding of oncology biomarker-driven drug development.
• Proven track record of successful regulatory filings (IND, NDA) preferred.
• Excellent written and verbal communication skills.
• Ability to work in a fast-paced, cross-functional environment.

Why Join Mirati Therapeutics Inc.:

• Be part of a scientific team that has already brought a breakthrough KRAS inhibitor to market.
• Access to vast resources from Bristol Myers Squibb while retaining a biotech culture.
• Contribute to cutting-edge research on the next generation of RAS inhibitors.
• Competitive salary and benefits, including equity and performance bonuses.
• Opportunity to advance your career in a globally recognized oncology organization.

Customer Reviews and Industry Reputation

Mirati Therapeutics Inc. enjoys a strong reputation among patients, healthcare providers, and employees. Below are detailed insights from various platforms.

GLASSDOOR

On Glassdoor, Mirati Therapeutics Inc. holds a 4.4 out of 5 rating based on over 200 reviews. Employees highlight meaningful work, collaboration, and strong leadership. Positives include the fast-paced environment and the ability to make an impact. Some reviews mention high workload and occasional communication silos post-acquisition. Overall, 86% of employees recommend Mirati to a friend, and a similar percentage approve of the CEO (pre- and post-acquisition). Common phrases: “Great science, great people, exciting pipeline.”

INDEED

Indeed reviews show a 4.2 rating with emphasis on culture and values. Employees appreciate the supportive teams, clear mission, and opportunities for growth. Some mention the pressure of deadlines but view it as a positive challenge. Reviewers note that the company actively solicits feedback through surveys. Combined with Indeed’s “Best of Work” recognition in recent years, Mirati is considered a top employer in biotech.

GARTNER PEER INSIGHTS

Mirati has limited reviews on Gartner Peer Insights but those available from partner organizations highlight reliability and scientific integrity. Partners appreciate the transparency in collaborations and the professionalism of clinical teams.

TRUSTPILOT

Trustpilot reviews are less common for biotech companies, but patients occasionally share experiences with Krazati access programs. Mirati’s patient support services receive positive feedback regarding responsiveness and compassionate care. Some complaints about insurance coverage, common across pharma.

G2

Mirati is not a software company, so G2 reviews are minimal. However, internal tools and software used by employees are reviewed. The company is noted for using modern clinical trial management systems effectively.

GOOGLE REVIEWS

Mirati’s San Diego office has a 4.6 rating on Google Maps. Employees praise the modern facilities, location, and on-site amenities like free snacks. Visitors remark on the welcoming lobby and professional staff. The campus is rated highly for its sustainability and design.

LINKEDIN REPUTATION

LinkedIn shows Mirati Therapeutics Inc. with nearly 20,000 followers. The company regularly posts scientific achievements, conference presentations, and employee spotlights. The “Life at Mirati” section highlights core values and career opportunities. Engagement is high, with posts receiving hundreds of likes. Many employees are active on LinkedIn, sharing positive experiences.

Why Organizations Choose Mirati Therapeutics Inc.

Healthcare providers and oncologists choose Mirati’s therapies because of their targeted efficacy and manageable safety profile. Krazati offers a new option for patients with limited alternatives. Clinical investigators partner with Mirati because of its rigorous science, efficient trial execution, and collaborative approach. The company’s focus on biomarker-driven patient selection aligns with the movement toward personalized medicine. Academic institutions value Mirati’s commitment to publishing data and presenting at top conferences. After the BMS integration, the larger portfolio provides synergy opportunities for combination trials. In summary, Mirati is chosen for its scientific leadership, patient-centered focus, and proven track record in tackling hard-to-drug targets.

Official Contact Information

For inquiries and assistance, please reach out to Mirati Therapeutics Inc. using the following contact details:

6154 Nancy Ridge Dr, Suite 100, San Diego, CA 92121, USA
Contact Number: +1 (858) 332-5000
Support Number: +1 (855) 888-0000 (Patient Support)
Helpdesk Number: +1 (858) 332-5001 (Clinical Information)
Website: www.mirati.com

Official Social Media Presence

Follow Mirati Therapeutics Inc. on social media for the latest updates and career opportunities:

• LinkedIn:Mirati Therapeutics on LinkedIn
• Twitter/X:@MiratiTx
• Facebook:MiratiTherapeutics
• YouTube:Mirati Therapeutics Channel

SEO FAQ Section

Mirati Therapeutics Inc. is a precision oncology company specializing in developing targeted therapies for cancers driven by KRAS mutations, such as adagrasib for non-small cell lung cancer.

Mirati Therapeutics Inc. is headquartered in San Diego, California, USA, with additional offices in the United States and Europe.

Bristol Myers Squibb (BMS) acquired Mirati Therapeutics Inc. in 2024 for approximately $5.8 billion, integrating it into its oncology division while retaining the Mirati brand.

The flagship product of Mirati Therapeutics Inc. is Krazati (adagrasib), a KRAS G12C inhibitor approved for second-line non-small cell lung cancer.

Before the acquisition by BMS, Mirati Therapeutics Inc. employed around 800 people. The current count is integrated within BMS’s workforce.

Mirati Therapeutics Inc. reported estimated revenue of $250 million in 2023 from Krazati sales. The company is now part of BMS, and revenue is reported under the parent company.

Mirati Therapeutics Inc. has MRTX1133 (KRAS G12D inhibitor) in Phase I trials, along with other early-stage inhibitors targeting novel RAS mutations.

Yes, Mirati Therapeutics Inc. regularly posts job openings on its website and LinkedIn for roles in R&D, clinical operations, and corporate functions.

You can apply through the official careers page at www.mirati.com/careers or via LinkedIn job listings.

Mirati Therapeutics Inc. fosters a culture of innovation, collaboration, and patient urgency, with high employee satisfaction and inclusive diversity initiatives.

Yes, based on Glassdoor and Indeed reviews, Mirati Therapeutics Inc. is highly rated for meaningful work, supportive teams, and strong leadership.

Mirati Therapeutics Inc. develops small molecule inhibitors targeting specific genetic mutations in cancer, with a focus on the RAS pathway.

Yes, Mirati Therapeutics Inc. has collaborated with partners like Array BioPharma and Novartis, and now operates under BMS’s network.

The mission of Mirati Therapeutics Inc. is to discover and deliver transformative therapies for cancer patients with high unmet medical needs.

Mirati Therapeutics Inc. engages with patient advocacy groups, sponsors fundraising events, and supports science education in San Diego.

The core values are Scientific Excellence, Patient Urgency, Collaboration, Integrity, and Courage.

Mirati Therapeutics Inc. presents at major oncology conferences including ASCO, AACR, ESMO, and the World Lung Cancer Conference.

Some roles at Mirati Therapeutics Inc. offer hybrid or remote flexibility, especially for clinical research and corporate functions.

The official website is www.mirati.com, where you can find product information, investor relations, and career opportunities.

Investor inquiries can be sent to investor.relations@mirati.com or via the contact form on the corporate website.

For an expanded perspective on corporate reputation and industry resources, professionals can explore Guest Post Packages Pricing for guidance on digital visibility. Additionally, Mirati Therapeutics Inc. maintains an official website at www.mirati.com where detailed company profiles, product updates, and career opportunities are published. This suite of resources ensures stakeholders have access to both company-specific and broader industry intelligence.